Rocket Pharma says gene therapy gets FDA review (RCKT:NASDAQ)

Rocket Pharmaceuticals (NASDAQ:RCKT) added ~11% in the premarket on Tuesday after the company announced that the FDA had accepted its resubmitted marketing application for its gene therapy candidate Kresladi. In June 2024, the FDA rejected the company’s biologics license application for ...